⁶⁸Ga-PENTIXAFOR PET/CT Captures Superscan in Refractory Multiple Myeloma.

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Radionuclide Therapy Pub Date : 2025-06-03 DOI:10.4274/mirt.galenos.2025.94557

Siven Kar, Harshita Gupta, Nusrat Shaikh, Vikram R Lele

{"title":"68Ga-PENTIXAFOR PET/CT Captures Superscan in Refractory Multiple Myeloma.","authors":"Siven Kar, Harshita Gupta, Nusrat Shaikh, Vikram R Lele","doi":"10.4274/mirt.galenos.2025.94557","DOIUrl":null,"url":null,"abstract":"We present a case of a 40-year-old male with refractory multiple myeloma, assessed using 68Gallium-PENTIXAFOR positron emission tomography/computed tomography (68Ga-PENTIXAFOR PET/CT), revealing widespread and intense C-X-C motif chemokine receptor 4 (CXCR4) expression in multiple osteolytic lesions across axial and appendicular skeletons, including bone marrow deposits. Despite undergoing autologous hematopoietic stem cell transplantation and multiple lines of maintenance therapy, the patient experienced disease relapse and progression. The term \"superscan\" typically refers to diffuse skeletal uptake in conventional bone scans, primarily seen in advanced metastatic cancers or metabolic bone diseases. CXCR4, crucial for tumor growth and metastasis, binds C-X-C motif chemokine 12 (CXCL12) to promote cancer progression. PENTIXAFOR, a CXCR4-targeted PET agent, facilitates imaging of such malignancies. While superscans using PET/CT are rare, our case underscores the utility of 68Ga-PENTIXAFOR PET/CT in evaluating CXCR4 expression in multiple myeloma, highlighting its potential as a diagnostic and prognostic tool in refractory disease management.","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"162-164"},"PeriodicalIF":0.9000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134946/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2025.94557","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

We present a case of a 40-year-old male with refractory multiple myeloma, assessed using ⁶⁸Gallium-PENTIXAFOR positron emission tomography/computed tomography (⁶⁸Ga-PENTIXAFOR PET/CT), revealing widespread and intense C-X-C motif chemokine receptor 4 (CXCR4) expression in multiple osteolytic lesions across axial and appendicular skeletons, including bone marrow deposits. Despite undergoing autologous hematopoietic stem cell transplantation and multiple lines of maintenance therapy, the patient experienced disease relapse and progression. The term "superscan" typically refers to diffuse skeletal uptake in conventional bone scans, primarily seen in advanced metastatic cancers or metabolic bone diseases. CXCR4, crucial for tumor growth and metastasis, binds C-X-C motif chemokine 12 (CXCL12) to promote cancer progression. PENTIXAFOR, a CXCR4-targeted PET agent, facilitates imaging of such malignancies. While superscans using PET/CT are rare, our case underscores the utility of ⁶⁸Ga-PENTIXAFOR PET/CT in evaluating CXCR4 expression in multiple myeloma, highlighting its potential as a diagnostic and prognostic tool in refractory disease management.

查看原文本刊更多论文

68Ga-PENTIXAFOR PET/CT捕获难治性多发性骨髓瘤的超扫描。

我们报告了一例40岁男性难固性多发性骨髓瘤，使用68Ga-PENTIXAFOR正电子发射断层扫描/计算机断层扫描（68Ga-PENTIXAFOR PET/CT）进行评估，发现C-X-C基序趋化因子受体4 （CXCR4）在多骨溶解病变中广泛而强烈地表达于轴向和阑尾骨，包括骨髓沉积。尽管接受了自体造血干细胞移植和多种维持治疗，患者仍经历了疾病复发和进展。术语“超扫描”通常是指常规骨扫描中的弥漫性骨骼摄取，主要见于晚期转移性癌症或代谢性骨疾病。CXCR4结合C-X-C基序趋化因子12 （CXCL12）促进肿瘤进展，对肿瘤生长和转移至关重要。PENTIXAFOR是一种靶向cxcr4的PET剂，可促进此类恶性肿瘤的成像。虽然PET/CT超扫描很少使用，但我们的病例强调了68Ga-PENTIXAFOR PET/CT在评估多发性骨髓瘤中CXCR4表达方面的应用，强调了其作为难治性疾病管理诊断和预后工具的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.